Здоровье
Омерос останавливает разработку терапии заболеваний почек после провала исследования
Omeros Corp. said Monday it will stop developing an experimental therapy to treat a certain type of kidney disease after a late-stage study failed and
Италия будет взимать с иностранцев 2000 евро в год за медицинское обслуживание
Foreigners living in Italy will be able to use the national health service after paying an annual fee of 2,000 euros ($2,109), the government said
Labcorp запускает трехэтапный анализ крови на болезнь Альцгеймера
Labcorp has begun selling U.S. doctors the first test for three blood biomarkers they say can detect signs of Alzheimer’s disease, speeding diagnosis of the
FDA не обнаружило нарушений на испытательных площадках в отношении вакцины Pfizer против болезни Лайма
A U.S. health regulator found no violations at clinical centres run by Care Access for Pfizer and French partner Valneva in a trial of a
Более 7 миллионов американцев получили обновленные вакцины от COVID
According to the US Department of Health and Human Services, more than 7 million Americans have received the updated COVID-19 vaccines, despite reports that some
Производитель лекарств GSK урегулировал еще один иск в Калифорнии по поводу лекарства от изжоги Zantac
GSK on Wednesday said it would confidentially settle another lawsuit in California alleging that its discontinued heartburn drug Zantac caused cancer, as the British drugmaker
Индия оправдала фирму по производству сиропа от кашля, связанную со смертью узбеков
The northern Indian state of Uttar Pradesh has authorised the resumption of most of the production at a plant owned by Marion Biotech that made
Суд одобрил реструктуризацию Mallinckrodt и сокращение возмещения расходов на опиоиды на $1 млрд.
Pharmaceutical company Mallinckrodt has received court approval for a bankruptcy plan that reduces by $1 billion the amount it owes to victims of the opioid
Alnylam отказывается расширять использование лекарств от сердечно-сосудистых заболеваний в США
Alnylam Pharmaceuticals said it will not expand the use of its drug to treat a potentially fatal heart condition in the U.S. after the Food
Число работодателей в США, платящих за лекарства для похудения, может почти удвоиться в 2024 году
The number of U.S. employers paying for obesity drugs, including Novo Nordisk’s Wegovy, which belongs to the GLP-1 class of drugs, could nearly double next